394 related articles for article (PubMed ID: 24473642)
1. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
Goetze TO; Reichart A; Bankstahl US; Pauligk C; Loose M; Kraus TW; Elshafei M; Bechstein WO; Trojan J; Behrend M; Homann N; Venerito M; Bohle W; Varvenne M; Bolling C; Behringer DM; Kratz-Albers K; Siegler GM; Hozaeel W; Al-Batran SE
Ann Surg Oncol; 2024 Jun; 31(6):4073-4083. PubMed ID: 38459418
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre.
Roselló S; Pizzo C; Huerta M; Muñoz E; Aliaga R; Vera A; Alfaro-Cervelló C; Jordá E; Garcés-Albir M; Roda D; Dorcaratto D; Tarazona N; Torondel S; Guijarro J; Sánchiz V; Gambardella V; Fleitas-Kanonnikoff T; Lluch P; Pascual I; Ferrández A; Sabater L; Cervantes A
ESMO Open; 2020 Nov; 5(6):e000929. PubMed ID: 33229503
[TBL] [Abstract][Full Text] [Related]
4. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy.
Ivey GD; Shoucair S; Delitto DJ; Habib JR; Kinny-Köster B; Shubert CR; Lafaro KJ; Cameron JL; Burns WR; Burkhart RA; Thompson EL; Narang A; Zheng L; Wolfgang CL; He J
World J Surg; 2022 Nov; 46(11):2751-2759. PubMed ID: 35861852
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis.
Yang SQ; Zou RQ; Dai YS; Li FY; Hu HJ
Updates Surg; 2024 Jan; 76(1):1-15. PubMed ID: 37639177
[TBL] [Abstract][Full Text] [Related]
6. Resected pancreatic adenocarcinoma: An Asian institution's experience.
Ng KYY; Chow EWX; Jiang B; Lim C; Goh BKP; Lee SY; Teo JY; Tan DMY; Cheow PC; Ooi LLPJ; Chow PKH; Lee JJX; Kam JH; Koh YX; Jeyaraj PR; Tan EK; Choo SP; Chan CY; Chung AYF; Tai D
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1393. PubMed ID: 33939335
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity.
Hill CS; Rosati LM; Hu C; Fu W; Sehgal S; Hacker-Prietz A; Wolfgang CL; Weiss MJ; Burkhart RA; Hruban RH; De Jesus-Acosta A; Le DT; Zheng L; Laheru DA; He J; Narang AK; Herman JM
Ann Surg Oncol; 2022 Apr; 29(4):2456-2468. PubMed ID: 35129721
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients.
Lim JE; Chien MW; Earle CC
Ann Surg; 2003 Jan; 237(1):74-85. PubMed ID: 12496533
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant strategies for pancreatic cancer.
Polistina F; Di Natale G; Bonciarelli G; Ambrosino G; Frego M
World J Gastroenterol; 2014 Jul; 20(28):9374-83. PubMed ID: 25071332
[TBL] [Abstract][Full Text] [Related]
10. Perioperative and long-term survival outcomes of pancreatectomy with arterial resection in borderline resectable or locally advanced pancreatic cancer following neoadjuvant therapy: a systematic review and meta-analysis.
Xue K; Huang X; Zhao P; Zhang Y; Tian B
Int J Surg; 2023 Dec; 109(12):4309-4321. PubMed ID: 38259002
[TBL] [Abstract][Full Text] [Related]
11. The Oncological Stress Test of Neoadjuvant Therapy: A Systematic Review in Outcomes of Neoadjuvant Therapy Compared to Upfront Resection Approach for Borderline Resectable Pancreatic Adenocarcinoma.
Ross SB; Popover J; Sucandy I; Christodoulou M; Pattilachan TM; Rosemurgy AS
Am Surg; 2024 Apr; ():31348241248703. PubMed ID: 38635295
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy and stereotactic body radiation therapy for borderline resectable pancreas adenocarcinoma: influence of vascular margin status and type of chemotherapy.
Palm RF; Boyer E; Kim DW; Denbo J; Hodul PJ; Malafa M; Fleming JB; Shridhar R; Chuong MD; Mellon EA; Frakes JM; Hoffe SE
HPB (Oxford); 2023 Sep; 25(9):1110-1120. PubMed ID: 37286392
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes in borderline and locally advanced pancreatic cancer with the addition of low-dose-rate brachytherapy to standard of care therapy.
Taylor RJ; Matthews GJ; Aseltine RH; Fields EC
Brachytherapy; 2024; 23(3):355-359. PubMed ID: 38402046
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic ductal adenocarcinoma complete regression after preoperative chemotherapy: Surgical results in a small series.
Pinelli D; Micalef A; Merelli B; Trezzi R; Amaduzzi A; Agnesi S; Guizzetti M; Camagni S; Fedele V; Colledan M
Cancer Treat Res Commun; 2023; 37():100770. PubMed ID: 37837717
[TBL] [Abstract][Full Text] [Related]
15. National failure to operate on early stage pancreatic cancer.
Bilimoria KY; Bentrem DJ; Ko CY; Stewart AK; Winchester DP; Talamonti MS
Ann Surg; 2007 Aug; 246(2):173-80. PubMed ID: 17667493
[TBL] [Abstract][Full Text] [Related]
16. Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer.
Liu M; Wei AC
Hematol Oncol Clin North Am; 2024 Jun; 38(3):629-642. PubMed ID: 38429197
[TBL] [Abstract][Full Text] [Related]
17. Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma.
Iyengar S; Nevala-Plagemann C; Garrido-Laguna I
Ther Adv Med Oncol; 2021; 13():17588359211045861. PubMed ID: 34552668
[TBL] [Abstract][Full Text] [Related]
18. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial.
Katz MH; Merchant NB; Brower S; Branda M; Posner MC; William Traverso L; Abrams RA; Picozzi VJ; Pisters PW;
Ann Surg Oncol; 2011 Feb; 18(2):337-44. PubMed ID: 20811779
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemotherapy and Radiation Improves Recurrence-free and Overall Survival in Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Kelley JK; Kolbeinsson H; Chandana S; Eastburg B; Frisch A; Parker J; Wright GP; Assifi MM; Chung M
Am Surg; 2024 Apr; ():31348241250043. PubMed ID: 38676648
[TBL] [Abstract][Full Text] [Related]
20. Comment on: Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
Underwood PW; Cloyd JM
Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38568860
[No Abstract] [Full Text] [Related]
[Next] [New Search]
